News
Portfolio Company News
- October 03, 2012
AcelRx Receives Notice of Eligibility for Centralized Review from European Medicines Agency for the Sufentanil NanoTab® PCA System
- October 02, 2012
Ablynx Collaborates with Merck to Develop
Therapeutic Nanobody Candidates
- October 02, 2012
Astex Pharmaceuticals Announces Initiation of SGI-110 Phase 2 Trial in Platinum-Resistant
Recurrent Ovarian Cancer Patients
- September 28, 2012
BioWorld Today: U.S. Patent Disclosure - AccelRx Pharmaceuticals, Inc. - September 27, 2012
Ablynx Proposes to Strengthen its Board with the Appointment of Dr. Roger Perlmutter and Dr. Russell Greig
- September 20, 2012
MacroGenics and Servier Enter Broad Strategic Alliance to Develop and Commercialize Three Anti-Cancer DART™ Products
- September 20, 2012
Ablynx and its Partner Advance Nanobody Candidate
ALX-0751 in Pre-Clinical Development
- September 18, 2012
Ablynx's First Inhaled Nanobody Successfully Completes Phase I Study
- September 11, 2012
Sunesis Pharmaceuticals to Implement One-Time Sample Size Increase to Phase 3 VALOR Trial in AML
- September 10, 2012
Proof of Concept Study in Well-Accepted Pre-Clinical Model Shows 90% Survival Benefit with Atu111 in Combination with Antibiotics
- September 10, 2012
Astex Pharmaceuticals Announces Initiation of HSP90 Inhibitor AT13387 Clinical Trial in
Prostate Cancer Patients
- September 06, 2012
Astex Pharmaceuticals, Cancer Research Technology and The Institute of Cancer Research
Announce Epigenetic Drug Discovery Collaboration
- September 05, 2012
BioWorld Today: News to Note - Trevena, Inc. - September 04, 2012
Scynexis, Inc. Announces Exclusive Licensing Deal for the Treatment of Canine Dry Eye
- September 04, 2012
Trevena, Inc. - TRV027 Shows Cardiac and Renal Benefits in Dog Heart Failure Model in Combination with Furosemide
- September 03, 2012
Trevena, Inc. - ß-Arrestin-Biased AT1R Promotes Cardiac Cell Survival During Acute Cardiac Injury
- August 28, 2012
Proacta Incorporated Announces IND Approval for PR610
- August 23, 2012
AcelRx Pharmaceuticals Initiates Third Phase 3 Clinical Trial for ARX-01, the Sufentanil NanoTab® PCA System, for the Treatment of Post-Operative Pain
- August 14, 2012
Aegerion Pharmaceuticals Announces Date of FDA Advisory Committee Review of Lomitapide NDA
- August 01, 2012
AcelRx Pharmaceuticals Receives Two Additional U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms
< Previous | Next >
